Relationship between Hemoglobin Levels and Risk for Suspected Non-Alcoholic Fatty Liver in Taiwanese Adults

10.4077/CJP.2014.BAD280

Chyi-Huey Bai；Ming-Shun Wu；Eddy Owaga；Shu-Yu Cheng；Wen-Harn Pan；Jung-Su Chang

alanine transaminase ； body iron levels ； metabolic syndrome ； non-alcoholic fatty liverdisease

The Chinese Journal of Physiology

57卷5期（2014 / 10 / 31）

286 - 294

英文

Body iron levels have recently been shown to be a strong predictor for non-alcoholic fatty liver disease (NAFLD). The aims of this study were to investigate the prevalence of NAFLD in a general adult population, and to investigate the relationship between body iron levels, NAFLD and the metabolic syndrome (MetS). 2186 adults participated in the third National Nutrition and Health Survey in Taiwan (NAHSIT, 2005-2008). The participants underwent anthropometry measurements and phlebotomy after an overnight fast, and those with excessive alcohol intake, iron overload of serum ferritin ＞ 600 ng/ml, hepatitis viral infection and hepatocellular carcinoma were excluded. Suspected NAFLD was diagnosed by three alanine transaminase (ALT) cut-points: cut-point 1: serum ALT＞40 U/l; cut-point 2: ALT≧25 U/l for male and ALT≧17 U/l for female; and cut-point 3: ALT≧35 U/l for male and ALT≧26 U/l for female. The prevalence proportion of suspected NAFLD among Taiwanese adults was 6.6% (cut-point 1), 36% (cut-point 2); and 14.3% (cut-point 3). Body iron levels were significantly higher in individuals with suspected NAFLD compared with those without. Distribution of hemoglobin levels, but not serum ferritin levels, by decade of age showed strong correlation with the prevalence of suspected NAFLD in individuals with MetS. Multivariate adjusted odds ratio (OR) showed that the best predictors for suspected NAFLD with the MetS were hemoglobin [OR 1.43 (1.21-1.68); P ＜ 0.0001] and hyperlipidemia [OR 1.52 (1.19-1.94); P = 0.0007]. In individuals without MetS, the adjusted OR of suspected NAFLD was markedly higher for hemoglobin [OR 1.25 (1.12-1.41); P ＜ 0.0001]. In conclusion, adults with high hemoglobin levels (14.4 μg/dl for male and 13.2 μg/dl for female) are at the greatest risk for developing abnormal liver function. Hemoglobin test should be considered as a part of clinical evaluation for patients with NAFLD.

1. Chang, C.C.,Chang, C.Y.,Huang, J.P.,Hung, L.M.(2012).Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats.Chinese J. Physiol,55,192-201.
   連結：
2. Chen, S.M.,Lin, H.Y.,Kuo, C.H.(2013).Altitude training improves glycemic control.Chinese J. Physiol,56,193-198.
   連結：
3. Chen, S.M.,Lin, H.Y.,Kuo, C.H.(2013).Altitude training improves glycemic control.Chinese J. Physiol,56,193-198.
   連結：
4. Cheng, C.C.,Lin, N.N.,Lee, Y.F.,Wu, L.Y.,Hsu, H.P.,Lee, W.J.,Tung, K.C.,Chiun, Y.T.(2010).Effects of Shugan-Huayu powder, a traditional Chinese medicine, on hepatic fibrosis in rat model.Chinese J. Physiol.,53,223-233.
   連結：
5. Demirci, C.,Gargili, A.,Kandil, A.,Cetinkaya, H.,Uyaner, I.,Boynuegri, B.,Gumustas, M.K.(2006).Inhibition of inducible nitric oxide synthase in murine visceral larva migrans: effects on lung and liver damage.Chinese J. Physiol,49,326-334.
   連結：
6. Lee, C.J.,Subeq, Y.M.,Lee, R.P.,Ke, C.Y.,Lin, N.T.,Hsu, B.G.(2011).Beneficial effects of enalapril on chlorhexidine digluconateinduced liver peritoneal fibrosis in rats.Chinese J. Physiol,54,225-234.
   連結：
7. Lin, C.H.,Ho, C.Y.,Liu, C.S.,Lin. W.Y.,Li, C.I.,Yang, C.W.,Bau, D.T.,Li, T.C.,Lin, C.C.(2012).Influence of adiponectin gene polymorphisms on adiponectin serum level and insulin resistance index in taiwanese metabolic syndrome patients.Chinese J. Physiol.,55,405-411.
   連結：
8. Lin, H.I.,Wang, D.,Leu, F.J.,Chen, C.F.,Chen, H.I.(2004).Ischemia and reperfusion of liver induces eNOS and iNOS expression: effects of a NO donor and NOS inhibitor.Chinese J. Physiol.,47,121-127.
   連結：
9. Adams, L.A.,Angulo, P.,Lindor, K.D.(2005).Nonalcoholic fatty liver disease.Can. Med. Assoc. J.,172,899-905.
10. Aigner, E.,Theurl, I.,Theurl, M.,Lederer, D.,Haufe, H.,Dietze, O.,Strasser, M.,Datz, C.,Weiss, G.(2008).Pathways underlying iron accumulation in human nonalcoholic fatty liver disease.Am. J. Clin. Nutr,87,1374-1383.
11. Amarapurkar, D.,Kamani, P.,Patel, N.,Gupte, P.,Kumar, P.,Agal, S.,Baijal, R.,Lala, S.,Chaudhary, D.,Deshpande, A.(2007).Prevalence of non-alcoholic fatty liver disease: population based study.Ann. Hepatol,6,161-163.
12. Aragon, G.,Younossi, Z.M.(2010).When and how to evaluate mildly elevated liver enzymes in apparently healthy patients.Cleve. Clin. J. Med.,77,195-204.
13. Chang, J.S.,Lin, S.M.,Chao, J.C.,Chen, Y.C.,Wang, C.M.,Chou,N.H.,Pan, W.H.,Bai, C.H.(2013).Serum ferritin contributes to racial or geographic disparities in metabolic syndrome in Taiwan.Public Health Nutr.,18,1-9.
14. Chang, J.S.,Lin, S.M.,Huang, T.C.,Chao, J.C.,Chen, Y.C.,Pan, W.H.,Bai, C.H.(2013).Serum ferritin and risk of the metabolic syndrome: a population-based study.Asia Pac. J. Clin. Nutr,22,400-407.
15. Chang, Y.,Ryu, S.,Sung, E.,Jang,Y.(2007).Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease.Clin. Chem.,53,686-692.
16. Chen, C.H.,Huang, M.H.,Yang, J.C.,Nien, C.K.,Yang, C.C.,Yeh, Y.H.,Yueh, S.K.(2006).Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.J. Clin. Gastroenterol.,40,745-752.
17. Chen, C.H.,Huang, M.H.,Yang, J.C.,Nien, C.K.,Yang, C.C.,Yeh, Y.H.,Yueh, S.K.(2007).Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan.J. Gastroenterol. Hepatol.,22,1482-1489.
18. Chen, C.J.,Wang, L.Y.,Yu, M.W.(2000).Epidemiology of hepatitis B virus infection in the Asia-Pacific region.J. Gastroenterol. Hepatol.,15(Suppl),E3-E6.
19. Choi, J.W.,Kim, S.K.,Pai, S.H.(2001).Changes in serum lipid concentrations during iron depletion and after iron supplementation.Ann. Clin. Lab. Sci.,31,151-156.
20. Dongiovanni, P.,Fracanzani, A.L.,Fargion, S.,Valenti, L.(2011).Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target.J. Hepatol.,55,920-932.
21. Fu, C.C.,Chen, M.C.,Li, Y.M.,Liu, T.T.,Wang, L.Y(2009).The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents.Ann. Acad. Med. Singapore,38,15-17.
22. Fujita, N.,Sugimoto, R.,Motonishi, S.,Tomosugi, N.,Tanaka, H.,Takeo, M.,Iwasa, M.,Kobayashi, Y.,Hayashi, H.,Kaito, M.,Takei, Y.(2008).Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.J. Hepatol.,49,702-710.
23. Green, R.M.(2003).NASH-hepatic metabolism and not simply the metabolic syndrome.Hepatology,38,14-17.
24. Hsiao, T.J.,Chen, J.C.,Wang, J.D.(2004).Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients.Int. J. Obes. Relat. Metab. Disord.,28,167-172.
25. Hsu, C.S.,Kao, J.H.(2012).Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan.J. Formos. Med. Assoc.,111,527-535.
26. James, P.E.,Lang, D.,Tufnell-Barret, T.,Milsom, A.B.,Frenneaux, M.P.(2004).Vasorelaxation by red blood cells and impairment in diabetes: reduced nitric oxide and oxygen delivery by glycated hemoglobin.Circ. Res.,94,976-983.
27. Kariv, R.,Leshno, M.,Beth-Or, A.,Strul, H.,Blendis, L.,Kokia, E.,Noff, D.,Zelber-Sagie, S.,Sheinberg, B.,Oren, R.,Halpern, Z.(2006).Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study.Liver Int.,26,445-450.
28. Kowdley, K.V.,Belt, P.,Wilson, L.A.,Yeh, M.M.,Neuschwander-Tetri, B.A.,Chalasani, N.,Sanyal, A.J.,Nelson, J.E.,Network, N.C.R.(2012).Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.Hepatology,55,77-85.
29. Lecube, A.,Hernandez, C.,Simo, R.(2009).Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload.Diabetes Metab. Res. Rev.,25,403-410.
30. Lee, J.K.,Shim, J.H.,Lee, H.C.,Lee, S.H.,Kim, K.M.,Lim, Y.S.,Chung, Y.H.,Lee, S.,Suh, D.J.(2010).Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology.Hepatology,51,1577-1583.
31. Lin, Y.C.,Chou, S.C.,Huang, P.T.,Chiou, H.Y.(2011).Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan.Ann. Hepato.,10,125-132.
32. Liu, C.J.(2012).Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.J. Gastroenterol. Hepatol.,27,1555-1560.
33. Ludwig, J.,Hashimoto, E.,Porayko, M.K.,Moyer, T.P.,Baldus, W.P.(1997).Hemosiderosis in cirrhosis: a study of 447 native livers.Gastroenterology,112,882-888.
34. Manousou, P.,Kalambokis, G.,Grillo, F.,Watkins, J.,Xirouchakis, E.,Pleguezuelo, M.,Leandro, G.,Arvaniti, V.,Germani, G.,Patch, D.,Calvaruso, D.,Mikhailidis, D.P.,Dhillon, A.P.,Burroughs, A.K.(2011).Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients.Liver Int.,31,730-739.
35. Marchesini, G.,Brizi, M.,Bianchi, G.,Tomassetti, S.,Bugianesi, E.,Lenzi, M.,McCullough, A.J.,Natale, S.,Forlani, G.,Melchionda, N.(2001).Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.Diabetes,50,1844-1850.
36. Mitsuyoshi, H.,Yasui, K.,Harano, Y.,Endo, M.,Tsujim, K.,Minami, M.,Itoh, Y.,Okanoue, T.,Yoshikawa, T.(2009).Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease.Hepatol. Res.,39,366-373.
37. Miyake, T.,Kumagi, T.,Hirooka, M.,Koizumi, M.,Furukawa, S.,Ueda, T.,Tokumoto, Y.,Ikeda, Y.,Abe, M.,Kitai, K.,Hiasa,Y.,Matsuura, B.,Onji, M.(2012).Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a communitybased cross-sectional study.J. Gastroenterol.,47,696-703.
38. Pan, W.H.,Le, M.S.,Chuang, S.Y.,Lin, Y.C.,Fu, M.L.(2008).Obesity pandemic, correlated factors and guidelines to define, screen and manage obesity in Taiwan.Obes. Rev.,9(Suppl 1),22-31.
39. Peng, Y.M.,Elson, C.E.(1971).Effect of iron on lipid metabolism of Tetrahymena pyriformis.J. Nutr,101,1177-1184.
40. Ruhl, C.E.,Everhart, J.E.(2003).Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.Gastroenterology,124,71-79.
41. Satchell, L.,Leake, D.S.(2012).Oxidation of low-density lipoprotein by iron at lysosomal pH: implications for atherosclerosis.Biochemistry,51,3767-3775.
42. Schwimmer, J.B.,Dunn, W.,Norman, G.J.,Pardee, P.E.,Middleton, M.S.,Kerkar, N.,Sirlin, C.B.(2010).SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease.Gastroenterology,138,1357-1364+e1351-e1352.
43. Senates, E.,Yilmaz, Y.,Colak, Y.,Ozturk ,O.,Altunoz, M.E.,Kurt, R.,Ozkara, S.,Aksaray, S.,Tuncer, I.,Ovunc, A.O.(2011).Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease.Metab. Syndr. Relat. Disord.,9,287-290.
44. Trak-Smayra, V.,Dargere, D.,Noun, R.,Albuquerque, M.,Yaghi, C.,Gannage-Yared, M.H.,Bedossa, P.,Paradis, V.(2009).Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery.Gut,58,825-832.
45. Tung, T.,Chiu, W.,Lin, T.,Shih, H.,Hsu, C.(2011).An exploration of prevalence and associated factors of nonalcoholic Fatty liver disease in the taiwanese police service.Iran. J. Public Health,40,54-62.
46. Valenti, L.,Dongiovanni, P.,Fargion, S.(2012).Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease.World J. Gastroenterol,18,3782-3786.
47. Westerbacka, J.,Corner, A.,Tiikkainen, M.,Tamminen, M.,Vehkavaara, S.,Hakkinen, A.M.,Fredriksson, J.,Yki-Jarvinen, H.(2004).Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk.Diabetologia,47,1360-1369.
48. Xu, C.,Yu, C.,Ma, H.,Xu, L.,Miao, M.,Li, Y.(2013).Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study.Am. J. Gastroenterol.,108,1299-1304.
49. Yan, C.G.,Ren, G.Y.,Wang, F.,Zhu, D.F.,Zhuang, Y.(2008).CD14-159 and -260 gene polymorphisms are associated with HBV-related cirrhotic injury in Chinese Han patients.Chinese J. Physiol.,51,94-99.
50. Yilmaz ,Y.,Senates, E.,Ayyildiz, T.,Colak, Y.,Tuncer, I.,Ovunc, A.O.,Dolar, E.,Kalayci, C.(2012).Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome.Eur. J. Clin. Invest.,42,411-418.
51. Younossi, Z.M.,Diehl, A.M.,Ong, J.P.(2002).Nonalcoholic fatty liver disease: an agenda for clinical research.Hepatology,35,746-752.
52. Yu, C.,Xu, C.,Xu, L.,Yu, J.,Miao, M.,Li, Y(2012).Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease.J. Hepatol.,56,241-247.